Record overview
Status and phase
Status: TERMINATED
Phase: PHASE2
Sponsor: QED Therapeutics, a BridgeBio company
Condition: Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
NCT02150967
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Registry Stop Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
The study was terminated early due to limited efficacy in Cohorts 2 and 3 (exploratory endpoints). Termination was not due to concerns about safety and had no impact on the primary efficacy analysis (ie, results reported for Cohort 1).